{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T15:10:05Z","timestamp":1750777805889,"version":"3.41.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,24]]},"DOI":"10.7759\/cureus.86659","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T14:44:21Z","timestamp":1750776261000},"source":"Crossref","is-referenced-by-count":0,"title":["The Clinical Applications of Psilocybin Therapies and Post-COVID Syndrome: A Comprehensive Narrative Review"],"prefix":"10.7759","author":[{"given":"Alfred","family":"Mathew","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roshan","family":"Dongre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seo Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alen","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellie","family":"Cherryholmes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Millad","family":"Mehrinfar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sagar","family":"Kamprath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-021-08848-3","article-title":"A review of persistent post-COVID syndrome (PPCS)","volume":"64","author":"Oronsky B","year":"2023","unstructured":"Oronsky B, Larson C, Hammond TC, Oronsky A, Kesari S, Lybeck M, Reid TR. A review of persistent post-COVID syndrome (PPCS). Clin Rev Allergy Immunol. 2023, 64:66-74. 10.1007\/s12016-021-08848-3","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102947","article-title":"Post-COVID syndrome. A case series and comprehensive review","volume":"20","author":"Anaya JM","year":"2021","unstructured":"Anaya JM, Rojas M, Salinas ML, et al.. Post-COVID syndrome. A case series and comprehensive review. Autoimmun Rev. 2021, 20:102947. 10.1016\/j.autrev.2021.102947","journal-title":"Autoimmun Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2020.07.037","article-title":"Anxiety and depression in COVID-19 survivors: role of inflammatory and clinical predictors","volume":"89","author":"Mazza MG","year":"2020","unstructured":"Mazza MG, De Lorenzo R, Conte C, et al.. Anxiety and depression in COVID-19 survivors: role of inflammatory and clinical predictors. Brain Behav Immun. 2020, 89:594-600. 10.1016\/j.bbi.2020.07.037","journal-title":"Brain Behav Immun"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross S","year":"2016","unstructured":"Ross S, Bossis A, Guss J, et al.. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016, 30:1165-80. 10.1177\/0269881116675512","journal-title":"J Psychopharmacol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson MW","year":"2014","unstructured":"Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014, 28:983-92. 10.1177\/0269881114548296","journal-title":"J Psychopharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2021.11.017","article-title":"Medicinal mushrooms: clinical perspective and challenges","volume":"27","author":"Panda SK","year":"2022","unstructured":"Panda SK, Luyten W. Medicinal mushrooms: clinical perspective and challenges. Drug Discov Today. 2022, 27:636-51. 10.1016\/j.drudis.2021.11.017","journal-title":"Drug Discov Today"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.32383\/appdr\/147281","article-title":"Herbal resources in the medication of depression during pandemic Covid-19","volume":"79","author":"Boles\u0142awska I","year":"2022","unstructured":"Boles\u0142awska I, Boles\u0142awska-Kr\u00f3l N, Kowalska K, Dady\u0144ska P, Przys\u0142awski J. Herbal resources in the medication of depression during pandemic Covid-19. Acta Poloniae Pharmaceutica - Drug Research. 2022, 79:17-31. 10.32383\/appdr\/147281","journal-title":"Acta Poloniae Pharmaceutica - Drug Research"},{"key":"ref8","article-title":"Psychedelics and mental health: an alternative strategy to treat mental impairments triggered or aggravated by COVID-19","volume":"28","author":"Bruno V","year":"2022","unstructured":"Bruno V, Wiazowski Spelta LE, Dur\u00e3o AC, Camarini R, Marcourakis T. Psychedelics and mental health: an alternative strategy to treat mental impairments triggered or aggravated by COVID-19. Altern Ther Health Med. 2022, 28:40-3.","journal-title":"Altern Ther Health Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2021.06.008","article-title":"Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in\u00a0vivo","volume":"109","author":"Shao LX","year":"2021","unstructured":"Shao LX, Liao C, Gregg I, Davoudian PA, Savalia NK, Delagarza K, Kwan AC. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in\u00a0vivo. Neuron. 2021, 109:2535-44.e4. 10.1016\/j.neuron.2021.06.008","journal-title":"Neuron"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"68","author":"Grob CS","year":"2011","unstructured":"Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, Greer GR. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011, 68:71-8. 10.1001\/archgenpsychiatry.2010.116","journal-title":"Arch Gen Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1080\/09699260.2022.2001140","article-title":"The therapeutic potential of psychedelic substances in hospice and palliative care","volume":"30","author":"Garcia ACM","year":"2022","unstructured":"Garcia ACM, de Oliveira Maia L. The therapeutic potential of psychedelic substances in hospice and palliative care. Prog Palliat Care. 2022, 30:1-3. 10.1080\/09699260.2022.2001140","journal-title":"Prog Palliat Care"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial","volume":"78","author":"Davis AK","year":"2021","unstructured":"Davis AK, Barrett FS, May DG, et al.. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2021, 78:481-9. 10.1001\/jamapsychiatry.2020.3285","journal-title":"JAMA Psychiatry"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris R","year":"2021","unstructured":"Carhart-Harris R, Giribaldi B, Watts R, et al.. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021, 384:1402-11. 10.1056\/NEJMoa2032994","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1590\/1516-4446-2020-1035","article-title":"Hallucinogens\/psychedelics resurrected as new tools in psychiatric therapy","volume":"43","author":"Dos Santos RG","year":"2021","unstructured":"Dos Santos RG, Bouso JC, Hallak JE. Hallucinogens\/psychedelics resurrected as new tools in psychiatric therapy. Braz J Psychiatry. 2021, 43:119-20. 10.1590\/1516-4446-2020-1035","journal-title":"Braz J Psychiatry"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1556\/2054.2021.00172","article-title":"Lifetime use of psychedelics is associated with better mental health indicators during the COVID-19 pandemic","volume":"5","author":"Cavanna F","year":"2021","unstructured":"Cavanna F, Pallavicini C, Milano V, Cuiule J, Tella RD, Gonz\u00e1lez P, Tagliazucchi E. Lifetime use of psychedelics is associated with better mental health indicators during the COVID-19 pandemic. J Psychedel Stud. 2021, 5:89-93. 10.1556\/2054.2021.00172","journal-title":"J Psychedel Stud"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.732028","article-title":"Psychedelic experiences during the early COVID-19 pandemic: findings from an international online survey","volume":"12","author":"Evens R","year":"2021","unstructured":"Evens R, Reiche S, Marek RM, et al.. Psychedelic experiences during the early COVID-19 pandemic: findings from an international online survey. Front Psychiatry. 2021, 12:732028. 10.3389\/fpsyt.2021.732028","journal-title":"Front Psychiatry"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris RL","year":"2016","unstructured":"Carhart-Harris RL, Bolstridge M., Rucker J, et al.. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016, 3:619-27. 10.1016\/S2215-0366(16)30065-7","journal-title":"Lancet Psychiatry"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.794780","article-title":"In silico studies on psilocybin drug derivatives against SARS-CoV-2 and cytokine storm of human interleukin-6 receptor","volume":"12","author":"Khan FI","year":"2021","unstructured":"Khan FI, Hassan F, Lai D. In silico studies on psilocybin drug derivatives against SARS-CoV-2 and cytokine storm of human interleukin-6 receptor. Front Immunol. 2021, 12:794780. 10.3389\/fimmu.2021.794780","journal-title":"Front Immunol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/psychoactives1010003","article-title":"Tripping to cope: coping strategies and use of hallucinogens during the COVID-19 pandemic in three cultural contexts","volume":"1","author":"Ona G","year":"2022","unstructured":"Ona G, R\u00e9v\u00e9sz D, Kohek M, et al.. Tripping to cope: coping strategies and use of hallucinogens during the COVID-19 pandemic in three cultural contexts. Psychoactives. 2022, 1:16-30. 10.3390\/psychoactives1010003","journal-title":"Psychoactives"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1178529","article-title":"Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive-compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial","volume":"14","author":"Ching TH","year":"2023","unstructured":"Ching TH, Grazioplene R, Bohner C, et al.. Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive-compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial. Front Psychiatry. 2023, 14:1178529. 10.3389\/fpsyt.2023.1178529","journal-title":"Front Psychiatry"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.716593","article-title":"Psychedelic-assisted psychotherapy after COVID-19: the therapeutic uses of psilocybin and MDMA for pandemic-related mental health problems","volume":"12","author":"Argento E","year":"2021","unstructured":"Argento E, Christie D, Mackay L, Callon C, Walsh Z. Psychedelic-assisted psychotherapy after COVID-19: the therapeutic uses of psilocybin and MDMA for pandemic-related mental health problems. Front Psychiatry. 2021, 12:716593. 10.3389\/fpsyt.2021.716593","journal-title":"Front Psychiatry"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.780696","article-title":"Psychedelic mushrooms in the USA: knowledge, patterns of use, and association with health outcomes","volume":"12","author":"Matzopoulos R","year":"2021","unstructured":"Matzopoulos R, Morlock R, Morlock A, Lerer B, Lerer L. Psychedelic mushrooms in the USA: knowledge, patterns of use, and association with health outcomes. Front Psychiatry. 2021, 12:780696. 10.3389\/fpsyt.2021.780696","journal-title":"Front Psychiatry"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103237","article-title":"Changes in substance supply and use characteristics among people who use drugs (PWUD) during the COVID-19 global pandemic: a national qualitative assessment in Canada","volume":"93","author":"Ali F","year":"2021","unstructured":"Ali F, Russell C, Nafeh F, Rehm J, LeBlanc S, Elton-Marshall T. Changes in substance supply and use characteristics among people who use drugs (PWUD) during the COVID-19 global pandemic: a national qualitative assessment in Canada. Int J Drug Policy. 2021, 93:103237. 10.1016\/j.drugpo.2021.103237","journal-title":"Int J Drug Policy"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths RR","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA, et al.. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016, 30:1181-97. 10.1177\/0269881116675513","journal-title":"J Psychopharmacol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1017\/ipm.2020.94","article-title":"Psychedelic science in post-COVID-19 psychiatry","volume":"38","author":"Kelly JR","year":"2021","unstructured":"Kelly JR, Crockett MT, Alexander L, et al.. Psychedelic science in post-COVID-19 psychiatry. Ir J Psychol Med. 2021, 38:93-8. 10.1017\/ipm.2020.94","journal-title":"Ir J Psychol Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1177\/02698811211064720","article-title":"The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation","volume":"36","author":"Rucker JJ","year":"2022","unstructured":"Rucker JJ, Marwood L, Ajantaival RJ, et al.. The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation. J Psychopharmacol. 2022, 36:114-25. 10.1177\/02698811211064720","journal-title":"J Psychopharmacol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-41199-x","article-title":"Longitudinal and transcultural assessment of the relationship between hallucinogens, well-being, and post-traumatic growth during the COVID-19 pandemic","volume":"13","author":"Bouso JC","year":"2023","unstructured":"Bouso JC, R\u00e9v\u00e9sz D, Ona G, et al.. Longitudinal and transcultural assessment of the relationship between hallucinogens, well-being, and post-traumatic growth during the COVID-19 pandemic. Sci Rep. 2023, 13:14052. 10.1038\/s41598-023-41199-x","journal-title":"Sci Rep"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01530-3","article-title":"Psychedelic therapy: a roadmap for wider acceptance and utilization","volume":"27","author":"Marks M","year":"2021","unstructured":"Marks M, Cohen IG. Psychedelic therapy: a roadmap for wider acceptance and utilization. Nat Med. 2021, 27:1669-71. 10.1038\/s41591-021-01530-3","journal-title":"Nat Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/238402-the-clinical-applications-of-psilocybin-therapies-and-post-covid-syndrome-a-comprehensive-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T14:44:53Z","timestamp":1750776293000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/238402-the-clinical-applications-of-psilocybin-therapies-and-post-covid-syndrome-a-comprehensive-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.86659","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,24]]}}}